Keytruda® (pembrolizumab) – Updated indication
November 7, 2023 - The FDA approved Merck’s Keytruda (pembrolizumab), in combination with trastuzumab, fluoropyrimidine-and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.
Top